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9-HODEConjugated linoleic acid (CLA) is thought to exert anticarcinogenic, antiatherogenic, anti-inﬂammatory and
weight loss effects. The impact on eicosanoid biosynthesis may be one of the mechanisms of its action. The aim
of this study was to establish whether CLA mixture supplemented daily after administration of carcinogen (7,
12-dimethylbenz[a]anthracene, DMBA) inﬂuenced the concentration of linoleic and arachidonic acid metabo-
lites: 13- or 9-hydroxyoctadecadienoic acids (13-, 9-HODE) and 15-, 12- or 5-hydroxyeicosatetraenoic acids
(15-, 12- or 5-HETE) and prostaglandin E2 (PGE2) in rat serum and DMBA-induced tumours. The correlations be-
tween polyunsaturated fatty acids (PUFA) and HETE and HODE contents in serum were also investigated.
Female Sprague–Dawley rats divided into three groups according to the diet (1% Bio-C.L.A., 2% Bio-C.L.A. and
plant oil in the control group)were used in the study. On the 50th day of life some of the animals in every dietary
groupwere administeredDMBA to induce tumours. Since that day, the ratswere fed one of the above-mentioned
diets. After 15 weeks the animals were sacriﬁced and blood and tumours were collected. HETE and HODE were
extracted using a solid-phase extraction (SPE) method on C18 columns and analysed with LC-MS/MS.
The results of our study showed that CLAdaily supplementation after carcinogen administration inﬂuence LA and
AA metabolite levels in serum and tumours. However, the ratios of eicosanoids having opposite effects (e.g. 12-
HETE/15-HETE), not concentrations of particular compounds, appear to be better indicators of pathological
processes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Conjugated linoleic acid (CLA) is a group of naturally occurring fatty
acids synthesised from linoleic acid by bacteria present in alimentary
tract of ruminant animals or as a result of endogenous conversion of
transvaccenic acid byΔ9-desaturase in tissues, especially themammary
glands [1]. CLA may be also synthetically produced by partial hydroge-
nation or alkali isomerisation of linoleic acid or oils rich in linoleic acid
(e.g. sunﬂower or safﬂower oils) [2,3]. That pathway is used for the in-
dustrial production of commonly available CLA preparations. CLA is a
mixture of positional and geometric isomers of linoleic acid (LA) withinoleic acid; COX, cyclooxygen-
cid; DMBA, 7,12-dimethylbenz
, hydroxyeicosatetraenoic acid;
S/MS, liquid chromatography–
lyunsaturated fatty acids; SEM,
. Jelińska),
aw.pl (H. Mojska),
.edu.pl (A. Tokarz).double bonds between carbon atoms 7 and 9, 8 and 10, 9 and 11, 10
and 12 or 11 and 13. They occur in a cis or trans conﬁguration. The
most prevalent form is the cis-9,trans-11 CLA isomer found in
ruminant-derived foods like milk, cheese andmeat [4]. The other active
isomer is trans-10,cis-12 CLA, present only in trace amounts in animal-
derived foods. However, it was found in equal proportions with cis-9,
trans-11 CLA in commercial CLA supplements [4]. As Yu et al. indicated,
these supplementsmay contain different concentrations of total CLA, its
two main active isomers and fatty acid proﬁle [5]. That may be due to
various compositions of fatty acids in the source plant oil used to CLA
synthesis and to conditions of isomerisation reactions [5].
CLA is thought to exert beneﬁcial effects in atherosclerosis preven-
tion [6], obesity reduction and cancer prevention [7,8]. Presently, the
mechanisms of its anti-carcinogenic action are being researched. An im-
pact of CLA on eicosanoid biosynthesis is thought to be one of them.
Eicosanoids are local, biologically active metabolites of 20-carbon
polyunsaturated fatty acids — arachidonic acid (AA), dihomo-
gamma-linolenoic acid (DGLA), and eicosapentaenoic acid (EPA).
They are synthesised by their oxidation by cyclooxygenase (COX)
and lipoxygenases (LOX). Arachidonic acid derivatives synthesised
by COX pathway belong to the best characterised compounds. They
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(TXA2). PGE2 appears to be a pro-inﬂammatory mediator and was
synthesised by some tumours [9]. Its elevated levels were noted in
tumours of digestive tract and in blood collected from vessels
draining a tumour area [10]. PGE2 production correlated with fatty
acid content in the diet and increased in animals fed a diet rich in
linoleic acid. In contrast to COX metabolites, hydroxyeicosatetraenoic
acids (HETE), synthesised from arachidonic acid by LOX were initially
considered unimportant compounds without biological activity. Since
different LOX isoforms are involved in arachidonic acid metabolism,
three main isomers of HETE are generated: 5-, 12- and 15-
hydroxyeicosatetraenoic acids (5-, 12-and 15-HETE). Nowadays they
are thought to participate in a number of pathological processes, such
as inﬂammation, atherosclerosis, hypertension or cancer [11]. 5- and
12-HETE are involved in tumour development [12]. 12-HETE may en-
hance tumour cell adhesion to endothelium, stimulate their prolifera-
tion, motility and angiogenesis and as a result plays a critical role in
metastasis [13]. Exogenous 5-HETE stimulates the proliferation and
growth of prostate, breast and lung cancer cells and acts as a survival
factor [11,14]. The inhibition of its synthesis by nordihydroguaiaretic
acid (NDGA), AA-861, MK-886 and Zileuton, which are 5-LOX inhibi-
tors, resulted in decreased proliferation and enhanced apoptosis of can-
cer cells. Contrary to pro-cancerogenic 5- and 12-HETE, 15-HETE
appears to have protective and anti-tumourigenic activity. It activates
peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear
transcription factor involved in epithelial differentiation and the arrest
of cell growth. As a result, 15-HETE inhibits proliferation and induces
apoptosis of prostate carcinoma or colorectal cancer cells [15,16]. Be-
sides 15-HETE, 13-hydroxyoctadecadienoic acid (13-HODE), linoleic
acid (LA) metabolite synthesised by 15-LOX-1, is another fatty acid
derivative exerting protective and anti-tumourigenic role. Studies on
rat skin or colon tumours indicate that 13-HODE may inhibit prolifera-
tion and induces apoptosis [17]. Another linoleic acid derivative, 9-
hydroxyoctadecadienoic acid (9-HODE), produced on the 5-LOX
pathway was described to stimulate cell proliferation [18]. Despite de-
veloping knowledge of various fatty acid LOX metabolite activities,
there is still little information on the impact of diet and dietary fat on
them, especially in tumour conditions. Fish oil containing diet signiﬁ-
cantly decreased 12-HETE, 15-HETE and 13-HODE levels in
azoxymethane-induced rat colon tumours, comparing to animals con-
suming corn oil containing diet [19]. That correlatedwith enhanced ap-
optotic index in the ﬁsh oil containing group. Similar observation was
made by Rose et al. who described signiﬁcant reduction of arachidonic
acid level as well as its LOX metabolites, 12- and 15-HETE, in breast tu-
mours developed in mice fed EPA or DHA containing diet, when com-
pared to linoleic acid high diet [20]. The authors explained inhibitory
effects of dietary ﬁsh oil on breast cancer growth and metastasis with
mechanisms that probably involved suppression of tumour eicosanoid
biosynthesis. Ten-week supplementation of the human diet with ﬁsh
oil has been shown to result in decreased production of 5-HETE and leu-
kotriene B4 by inﬂammatory cells [21]. In another experiment Espada
et al. observed that chia oil rich in n-3 fatty acids (63% α-linolenic acid
and 21% linoleic acid) decreased 12-HETE level in murine mammary
gland adenocarcinomas, compared to safﬂower oil (76% linoleic acid
and 0.24% α-linolenic acid) and control diet (12% linoleic acid and
3.5% α-linolenic acid) in mice [22]. Ramsden et al. noted that lower die-
tary linoleic acid levels reduced the concentration of 13- and 9-HODE
[23]. It was also observed that in breast cancer cells, trans-10,cis-12 CLA
decreased cell growth and the production of hydroxyeicosatetraenoic
acid (5-HETE), which is an arachidonic acid metabolite, synthesised by
5-lipoxygenase (5-LOX) [24].
The aim of this study was to establish if commercially available in
pharmacies or health food stores conjugated linoleic acids mixture
(cis-9,trans-11 isomer and trans-10,cis-12 isomer in equal proportions),
supplemented daily after carcinogenic agent administration inﬂuenced
the concentration of linoleic and arachidonic acid derivatives in ratserum and 7,12-dimethylbenz[a]anthracene (DMBA)-induced tumours.
The correlations between polyunsaturated fatty acids (PUFA) and HETE
contents in serum were also investigated.
2. Materials and methods
2.1. Standards and chemicals
Eicosanoid standards: 15-hydroxyeicosatetraenoic acid (15-HETE),
12-hydroxyeicosatetraenoic acid (12-HETE), 5-hydroxyeicosatetraenoic
acid (5-HETE), 13-hydroxyoctadecadienoic acid (13-HODE), 9-
hydroxyoctadecadienoic acid (9-HODE) and prostaglandin E2 (PGE2)
were purchased from Cayman Chemical Company, USA. LC-MS grade
methanol, acetonitrile, ethanol and solid-phase extraction (SPE) car-
tridges (Bakerbond C18, 500 mg/3 mL) were purchased from J.T. Baker.
Formic acid and 7,12-dimethylbenz[a]anthracene (DMBA) were pur-
chased from Sigma-Aldrich. Deionised water was puriﬁed on the water
puriﬁcation system (Direct Q, Millipore). Bio-C.L.A. was obtained from
Pharma-Nord, Denmark.
2.2. Animals and experiment
Female Sprague–Dawley rats (n = 50), purchased from Division of
Experimental Animals, Department of General and Experimental Pa-
thology (Medical University of Warsaw, Poland), were used in the
study. The animals (30 days old) were fed the rat standard diet
(Labofeed H, Feed and Concentrates Production Plant, A. Morawski,
Kcynia, Poland) ad libitum. The diet was composed of the following
compounds (per 1 kg): protein (222 g), fat (50 g), ﬁbre (45 g), ash
(60 g), carbohydrates (500 g), vitamin A (15,000 IU), vitamin D3
(1000 IU), vitamin E (90 mg), vitamin K3 (3 mg), vitamin B1 (21 mg),
vitamin B2 (16 mg), vitamin B6 (17 mg), vitamin B12 (80 μg),
pantothenic acid (30 mg), folic acid (5 mg), nicotinic acid (133 mg),
Ca (9.5 g), P (7.7 g), Mg (3 g), K (10 g), Na (2 g), Cl (2.5 g), S (1.9 g),
Fe (170 mg), Mn (68 mg), Zn (78 mg), Cu (16 mg), Co (0.3 mg), I
(0.2 mg), and Se (0.4 mg). Linoleic acid was the main fatty acid in the
rat chow. Its concentration was about 40%, followed by α-linolenic
acid (22%), oleic acid (16%), palmitic acid (13%) and stearic acid (3%).
Other fatty acids were in trace concentrations. Since the 50th day of
life the rats were given intragastrically 0.15 mL/day of oil rich in linoleic
acid (groups A1 and G1) or Bio-C.L.A. (Pharma-Nord, Denmark) (other
groups) in two concentrations. Groups B1 and D1 were given 0.15 mL/
day of Bio-C.L.A., which correspondedwith 1% content in a diet, whereas
groups C1 and E1were given 0.30 mL/day, equal to 2%CLA in a diet [25].
Dietary groups numbered 8 (A1, G1, D1 and E1) or 9 (B1 and C1) ani-
mals. Fatty acid proﬁles (%) in administered oils are introduced in
Fig. 1. When 50 days old, the animals from groups A1, B1 and C1 were
administered intragastrically a single dose (80 mg/kg body weight) of
carcinogenic agent — 7,12-dimethylbenz[a]anthracene (DMBA, Sigma-
Aldrich) to induce tumours. Fifteen weeks after DMBA administration,
the rats were decapitated. Blood and tumours were collected. Serum
was obtained by centrifugation of blood at 4 °C at 3000 rpm. Serum
and tumours were stored at−20 °C until further analyses.
The experiment was approved by The Ethical Committee on Animal
Experiments at the Medical University of Warsaw.
2.3. HETE and HODE determination
2.3.1. Sample preparation
Methanol (0.5 mL) was added to serum samples (0.4 mL), followed
by water (4 mL), so as to obtain approximately 10% methanol. Tumour
samples (approximately 0.2 g)were homogenised inwater (2mL). Dur-
ing that action the homogeniser was kept in crushed ice. The samples
were incubated at 4 °C for 30 min then tumour samples were
centrifugated at 3000 rpm for 5 min to remove precipitated proteins.
Tumour supernatants and serum samples were loaded onto SPE
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Fig. 1. Fatty acid proﬁles (%) in administered oils.
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nol followed by 10 mL water. The cartridges were washed with 2 mL
water and 2 mL 10% methanol. The fatty acid metabolites were eluted
with 100% methanol (3 × 0.5 mL) and evaporated to dryness in a nitro-
gen stream at 37 °C. The dry residues were reconstituted in 200 μL mix-
ture of ethanol and water (1:2, v/v) and ﬁltered through 0.22 μm ﬁlters
(Ultrafree-MC, Durapore PVDF, 0.22 μm, Millipore, USA) [26].
2.3.2. LC-MS/MS analysis
The analysis of linoleic and arachidonic acid metabolites present in
serum and tumour tissue was carried out using modiﬁed method by
Masoodi et al. [27,28]. Chromatographic separation was performed on
Dionex UltiMate 3000 HPLC system, on C18 column (Luna 5 μm, C
18(2), 150 × 2 mm, Phenomenex, USA) with guard column packed
with the same material. The ﬂow rate was 0.5 mL/min for 12 min,
then it was increased to 1 mL/min. The column temperature was
maintained at 30 °C. The injection volume was 100 μL. The analysis
was performed in a gradient system, where the mobile phase was
composed by mixing two solvents: A (water with 0.2% formic acid)
and B (acetonitrile/methanol, 75:25, v/v with 0.2% formic acid).
The percentage content of solvent B in the mobile phase volume
was 40% from 0.0 to 1.0 min, increased to 90% between 1.0 and
10 min and maintained to 12 min. Then the content of solvent B
was decreased to 40% between 12.0 and 12.1 min. This concentration
was maintained to 14 min.
Eicosanoids were quantiﬁed with 3200 Q-Trap mass spectrometer
(AB Sciex, Framingham, USA) operating in negative ionmode, andmul-
tiple reaction monitoring (MRM) method was performed. MS condi-
tions were: curtain gas: nitrogen (CUR = 20), source temperature:
600 °C, ion spray capillary voltage: −4.500 V, dwell-time: 50 ms.
MRM transitions and collision energy settings are summarised in
Table 1 [28]. The method described enabled good separation as well asTable 1
Multiple reaction monitoring (MRM) for the LC/MS/MS analysis of selected eicosanoids.
Compound MRM (m/z) Collision energy (eV)
PGE2 351.1 → 271.2 −22
13-HODE 295.1 → 195.3 −24
9-HODE 295.2 → 171.0 −26
15-HETE 319.1 → 219.0 −16
12-HETE 319.2 → 179.0 −18
5-HETE 319.1 → 114.9 −18fast (14min) analysis of compounds,which very low levelsweredetect-
ed. The method is characterised by good precision and recoveries. The
exact validation parameters were described previously [28]. The preci-
sion, expressed as the relative standard deviation of the mean (RSD%),
ranged from 5% (9-HODE) to 13% (15-HETE). Recoveries of eisosanoids
were within 77% (9-HODE)–137% (5-HETE) range.2.4. HETE and HODE correlations with CLA
2.4.1. CLA determination
CLA determination was performed with gas chromatography (GC),
using capillary column and ﬂame-ionization detector. The procedure
was precisely described by Białek et al. [25].2.5. Statistical analysis
Statistica 10.0 software (StatSoft, USA) was used for the statistical
analysis. The normality assumptionswere checkedwith Shapiro–Wilk's
test. ANOVA, followed by Tukey's range test with unequal sample size,
was used to compare differences between groups if the normality and
variance homogeneity assumptions were fulﬁlled. Otherwise non-
parametric Kruskal–Wallis test with post-hoc Dunn's test was per-
formed. The acceptable level of signiﬁcance was established at
p b 0.05. Spearman's coefﬁcients were used to estimate potential corre-
lations between circulating CLA isomers (cis-9,trans-11 CLA and trans-
10,cis-12 CLA) and linoleic and arachidonic acid metabolites. Data are
presented as means ± SEM.
Fisher's exact test was used to compare tumour incidence among
groups. The power of the study was over 80%, with 95% conﬁdence
interval.Table 2
Mammary tumours in DMBA-treated rats according to dietary groups.
Dietary group Supplementation Total rat
number
Tumour incidence
at necropsy (%)
Tumour weight
ranges (g)
A1 Oil 8 88a 0.45–11.93
B1 1% CLA 9 67 0.62–8.51
C1 2% CLA 9 33a 1.12–4.48
a Statistically signiﬁcant differences at p b 0.05were calculatedwith Fisher's exact test.
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The number of tumour-bearing rats in A1 and B1 groupswas report-
ed by Białek et al. [25]. In the present paper it is shown in Table 2,
complemented with C1 group. The highest tumour induction was ob-
served in A1 group (88%), supplementedwith oil. The tumour incidence
in groups supplemented with CLA was lower: 67% in B1 group fed 1%
CLA and 33% in C1 group, fed 2% CLA.
3.1. HETE, HODE and PGE2 determination
In our study, we determined 6 eicosanoids, metabolites of linoleic
acid (13- and 9-HODE) and arachidonic acid (15-HETE, 12-HETE, 5-
HETE and synthesised by COX–PGE2) in rat serum and tumours. We
also analysed statistically ratios of various eicosanoids having opposite
effects in carcinogenesis: 12-HETE/15-HETE, 5-HETE/15-HETE, 12-
HETE/13-HODE and 5-HETE/13-HODE.
5-HETE was the main hydroxy fatty acid extracted from serum of all
dietary groups, following by 9-HODE, 12-HETE and 13-HODE, whereas
15-HETE showed the lowest levels (Table 3). We observed signiﬁcant
differences in the concentrations of hydroxy fatty acids extracted from
serum of rats fed various diets. In the non-DMBA-treated groups (G1,
D1, E1) the lowest levels of eicosanoids were observed in D1 group,
fed 1% CLA (Table 3). Statistically signiﬁcant differences were between
D1 and A1, aswell as betweenD1 and C1 groups. The lowest serumcon-
centrations of LA and AA metabolites were noted in A1 group, fed with
oil (Table 3). They differed signiﬁcantly from CLA fed groups — B1 and
C1. However, the contents of HETE and HODE extracted from B1
group were signiﬁcantly increased when compared to the C1 group
(Table 3). PGE2 was undetectable in rat serum of all dietary groups,
both DMBA-treated and non-DMBA-treated.
Serum eicosanoid ratios were signiﬁcantly higher (p b 0.05) in A1
group (12-HETE/15-HETE (6.7), 5-HETE/15-HETE (20.8), 12-HETE/13-
HODE (2.9) and 5-HETE/13-HODE (9.3)) compared to B1 (2.4, 6.1, 1.2,
3.0 respectively) and C1 groups (4.0, 5.2, 0.8, 1.1 respectively) (Fig. 2).
5-HETE/15-HETE, 5-HETE/13-HODE and 12-HETE/13-HODE ratios
were slightly increased in B1 group compared to C1 group (Fig. 2).
Therewere few if any differences in eicosanoid ratios in serumof the an-
imals from non-DMBA-treated groups (data not shown).
B1 group showed the highest level of all metabolites in tumour tis-
sues (Table 4). They were signiﬁcantly higher compared to A1 and C1
groups. Similarly to results received from serum, LA and AA metabolite
concentrations in A1 and C1 groups did not differ signiﬁcantly, except
12-HETE level, which was statistically increased in A1 as compared to
C1 group. Unlike in serum, 12-HETE contents were lower in tumours
from every dietary group than other AA and LA metabolites.
PGE2, not detected in serum, was detected in tumour tissues
(Table 4). The highest concentration of that eicosanoid was determined
in B1 group (1119ng/g tissue). It differed signiﬁcantly fromA1 (153ng/g
tissue) and C1 (103 ng/g tissue) groups. The contents of PGE2, which is
AA COX metabolite, were also lower than AA LOX derivatives — 15-,
12- and 5-HETE in A1 and C1 groups.
Similarly to serum, 12-HETE/15-HETE and 12-HETE/13-HODE ratios
were signiﬁcantly higher in A1 group (0.81 and 0.92 respectively)Table 3
Concentrations of linoleic and arachidonic acid metabolites in serum of DMBA-treated or non-
Group A1 B1 C1
Hydroxy fatty acid +DMBA
13-HODE 22.0 ± 4.9ab 435.8 ± 219.7a 233.8 ±
9-HODE 46.6 ± 10.4a 1002.0 ± 632.9a 463.2 ±
15-HETE 9.4 ± 1.9a 196.7 ± 80.3ab 49.1 ±
12-HETE 61.5 ± 8.4a 455.7 ± 164.3ab 166.3 ±
5-HETE 195.8 ± 42.2a 1074.0 ± 155.4ab 221.0 ±
Data are expressed asmean ± SEM. Values sharing a letter (a, b, c or d) in one row are signiﬁcan
other values of +DMBA groups and a value from the−DMBA group (G1, D1, E1) was comparcompared to B1 (0.62 and 0.47 respectively) and C1 (0.41 and 0.39 re-
spectively) groups (Table 4). The other two analysed hydroxy fatty
acid ratios (5-HETE/15-HETE and 5-HETE/13-HODE) were also higher
in A1 group than in B1 and C1 groups, although the differences were
not signiﬁcant (Table 4). There were slight if any differences in eicosa-
noid ratios between B1 and C1 groups.
3.2. HETE and HODE correlations with CLA
We found that AA metabolite levels (HETE) negatively correlated
with CLA circulating in serum. At p b 0.05 signiﬁcant correlations were
noted especially between trans-10,cis12 CLA and 15-HETE (r =
−0.60), 12-HETE (r = 0.59), and 5-HETE (r = 0.71) (Table 5).
4. Discussion
Diet plays a critical role in the aetiology of cancers and dietary fat
and particular fatty acids attract the interest of researchers [29,30].
CLA has taken a special place among other fatty acids since Pariza
et al. discovered anti-tumourigenic activity of fried beef in 1979, and
some years later a compound responsible for that action [31,32]. The
discovery caused CLA to be regarded as functional food [33]. Despite
many epidemiological studies and animal experiments [34,35], the
mechanisms of anticancer activity of CLA are still disputed.
In our experiment, we made an attempt to estimate the inﬂuence of
CLA mixture, commercially available in pharmacies or health food
stores, supplemented daily in two concentrations (1% or 2%) after car-
cinogen administration on the contents of LA and AA metabolites in
rat serum and chemically induced tumours. We also wanted to check
the possibility of using these metabolites as markers in carcinogenesis.
In the similar studies two models of CLA preparations have been
used. One of them is based on a mixture containing usually equal
amounts of two major CLA isomers (cis-9,trans-11 CLA and trans-10,
cis-12 CLA) [36]. In the other one the focus on effects of separate CLA
isomers has been put forward [37,38]. In some experiments mammary
tumour development, mammary epithelial mass and size of the termi-
nal end buds were reduced when rats fed both CLA isomer mixture or
one of the CLA puriﬁed isomers [39]. On the other side, studies with pu-
riﬁed CLA isomers (cis-9,trans-11 CLA and trans-10,cis-12 CLA) fed to
laboratory animals or given to the cancer cell lines indicated that they
may exert differential effects on carcinogenesis of some types of tu-
mours as well as on fatty acid proﬁle in various tissues [40]. In the
light of that result, some authors suggested that using a single CLA iso-
mers “ismore appropriate than their equal-amountmixture”, because it
enables better observation of CLA anticancerogenic mechanisms [41].
Despite of that advantage of separate CLA isomers, after thorough inves-
tigation of the CLA preparations, commercially available in pharmacies
or healthy food stores in some European Union countries, we decided
to choose the mixture of isomers, rather than separate isomers. Such
decision brings some limitations in observation of CLA mechanisms of
activity. However, it enabled us to provide similar conditions to those
of humans taking CLA supplements.
The lowest tumour incidence was noted in C1 group supplemented
with 2% CLA (33%), followed by B1 group fed 1% CLA (67%) (Table 2).DMBA-treated rats supplemented with CLA or oil [ng/mL serum].
G1 D1 E1
−DMBA
60.8b 240.9 ± 73.2c 37.5 ± 7.2cd 341.4 ± 92.0d
119.4a 388.2 ± 84.8cd 74.7 ± 15.2cd 621.3 ± 240.9d
23.3b 139.3 ± 45.7c 19.0 ± 4.8cd 129.6 ± 39.7d
57.0b 468.0 ± 265.7c 76.6 ± 12.7cd 402.2 ± 265.7d
43.4b 1032.4 ± 238.6c 99.5 ± 41.7cd 1006.7 ± 252.7d
tly different (p b 0.05). A value from the+DMBAgroup (A1, B1, C1) was compared to the
ed to the other values of−DMBA groups.
Fig. 2. Serum eicosanoid ratios in DMBA-treated dietary groups. A — 12-HETE/15-HETE ratio, B — 5-HETE/15-HETE ratio, C — 5-HETE/13-HODE ratio, and D — 12-HETE/13-HODE ratio.
Values sharing a letter (a or b) are signiﬁcantly different (p b 0.05). Small square inside large box —mean, large box — standard error of mean (SEM), whiskers — conﬁdence level.
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results conﬁrmed the knowledge of anti-tumourigenic CLA activity [8,
42]. That indicates that higher doses of CLA are more efﬁcient in inhibi-
tion of breast cancer.
Unexpectedly, in our study we noted the highest levels of LA and AA
metabolites in B1 group supplemented with lower (1%) CLA dose,
followed by C1 group, where tumour incidence was decreased by 21%
and 55% respectively, when compared to A1 group. The animals from
A1 group were fed the oil rich in linoleic acid (Fig. 1). However, the ei-
cosanoid contents in that group were the lowest. On the other hand,
the rats in that group developed the highest number of tumours (88%
incidence). That was surprising because linoleic acid is a substrate for
AA synthesis by delta-6- and delta-5-desaturases and elongases. Arachi-
donic acid is further converted to hydroxyeicosatetraenoic acids or to
PGE2. 12-HETE and 5-HETE show tumourigenic and metastatic activityTable 4
Concentrations of linoleic and arachidonic acidmetabolites in tumour tissue [ng/g tissue].
Hydroxy fatty acid A1 B1 C1
13-HODE 785.2 ± 182.4a 1888.7 ± 381.2ab 714.0 ± 165.3b
9-HODE 613.6 ± 179.9a 1509.0 ± 221.0ab 645.4 ± 180.9b
15-HETE 738.0 ± 212.3a 1292.9 ± 147.1ab 677.5 ± 191.2b
12-HETE 654.0 ± 235.7 773.7 ± 137.3a 276.2 ± 74.4a
5-HETE 406.5 ± 218.7 1154.4 ± 208.0a 472.0 ± 151.4a
PGE2 153.0 ± 45.9a 1119.2 ± 235.0ab 103.2 ± 48.7b
12-HETE/15-HETE 0.81 ± 0.23a 0.62 ± 0.10 0.41 ± 0.09a
5-HETE/15-HETE 0.73 ± 0.12 0.70 ± 0.15 0.70 ± 0.16
12-HETE/13-HODE 0.92 ± 0.37a 0.47 ± 0.09 0.39 ± 0.10a
5-HETE/13-HODE 0.72 ± 0.16 0.58 ± 0.17 0.66 ± 0.15
Data are expressed asmean ± SEM. Values sharing a letter (a or b) are signiﬁcantly differ-
ent (p b 0.05).andwe could expect higher concentrations of these compounds. Never-
theless, that result may be explained by Rett and Whelan [43].
Reviewing the literature, they observed: “there are no evidence to sug-
gest that increased intake of LA would modify tissue AA content” and
that may cause low eicosanoid concentrations [43].
Several studies suggested that trans-10,cis-12 CLA reduced synthesis
of 5-HETE but not 12- and 15-HETE in mouse mammary tumour cells
[24,44]. However, other studies present contrary results. Urquhart
et al. observed that the lower concentrations of cis-9,trans-11 CLA and
trans-10,cis-12 CLA isomers (50 μM) individually inhibited the overall
prostaglandin production but tested at a high levels (100 μM) only
cis-9,trans-11 CLA demonstrated that action. Trans-10,cis-12 CLA in a
high concentration exerted pro-inﬂammatory activity and caused stim-
ulation of prostaglandins [45]. In the present study we noted the most
effective synthesis of eicosanoids extracted from tumours and serumTable 5
Correlations between circulating CLA isomers and linoleic and arachidonic acid
metabolites.
Correlation Correlation coefﬁcient (r) P value
13-HODE vs. cis-9,trans-11 CLA 0.13 0.598
13-HODE vs. trans-10,cis-12 CLA −0.18 0.499
9-HODE vs. cis-9,trans-11 CLA −0.07 0.779
9-HODE vs. trans-10,cis-12 CLA −0.47 0.064
15-HETE vs. cis-9,trans-11 CLA −0.13 0.606
15-HETE vs. trans-10,cis-12 CLA −0.60 0.018
12-HETE vs. cis-9,trans-11 CLA −0.17 0.510
12-HETE vs. trans-10,cis-12 CLA −0.59 0.016
5-HETE vs. cis-9,trans-11 CLA −0.30 0.226
5-HETE vs. trans-10,cis-12 CLA −0.71 0.002
Statistically signiﬁcant p values (p b 0.05) are in bold.
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mented with 2% CLA were similar to those obtained from A1 group, ex-
cept 12-HETE levels. The similar results were described by Comba et al.,
where 12-HETE concentration was lower in mammary tumours inmice
from the group fed a diet of the highest LA concentration [46].
The highest concentrations of PGE2 were also detected in tumours
from B1 group, where cancer incidence was 67%. PGE2 is a well-
known cancer mediator, playing an important role in cell proliferation,
survival, migration and angiogenesis of various types of tumours. Its el-
evated concentrations have been detected in breast, prostate, colon,
pancreatic, lung or ovarian cancers [47–49]. PGE2 production was also
increased in the childhood neuroblastoma, where the compound en-
ables tumour cell survival and proliferation [50]. Contrary, Lalier et al.
observed that increased intracellular PGE2 levels induced apoptosis of
colon cancer cells, dependent on the expression of anticancer protein
Bax [51]. These results highlight the complex role of PGE2 in carcinogen-
esis. The results of present experiment corresponds with our previous
results, as well as those by Sasaki et al., indicating that PGE2 may be
one of the agents affecting tumourigenesis, but it is not of the crucial im-
portance [52,53].
Our results suggest that values of chosen LA and AA metabolites are
not very precise factors for reﬂecting dietary CLA inﬂuence on the or-
ganism in pathological (cancer) conditions. For that reason the compar-
ison of various hydroxy fatty acid ratios appears interesting and
important. We compared 12-HETE/15-HETE, 5-HETE/15-HETE, 12-
HETE/13-HODE and 5-HETE/13-HODE ratios, which are also used by
other authors [46]. Whereas there were few if any differences in eicos-
anoid ratios in serum of non-DMBA-treated groups, we found interest-
ing relationships between them, both in serum and tumours of
DMBA-treated rats. Hydroxy fatty acid ratios were signiﬁcantly higher
in serum obtained from the rats from A1 group supplemented with LA
rich oil and developing the largest number of tumours, than those
from B1 and C1 groups, fed with 1% or 2% CLA, respectively. Cancer inci-
dence in that group is also lower. What is more, except 12-HETE/15-
HETE, the ratios were lower in C1 group (the lowest tumour incidence),
although the differences were not signiﬁcant (Fig. 2). Eicosanoids cho-
sen to those ratios exert opposite actions. 5-HETE and 12-HETE stimu-
late tumourigenesis and metastasis. 15-HETE and 13-HODE act
adversely [12,17].
12-HETE/15-HETE and 12-HETE/13-HODE ratios appear to be of
great interest in tumour tissue. The lower values of the eicosanoid ratios
in tumours from B1 and especially C1 group correlate with decreased
tumour incidence in these groups. The similar relationship was de-
scribed by Comba et al., who noted the highest 13-HODE/12-HETE
(which means the lowest 12-HETE/13-HODE) ratio in tumours from
the group of the decreased metastasis number and increased survival
[46].
Another interesting fact resulting from our study is the correla-
tion between circulating CLA isomers and HETE and HODE concen-
trations in serum. We found strong negative correlations between
trans-10,cis-12 CLA and 15-, 12- and 5-HETE. This result corresponds
partially with experiments described by Kim et al., where trans-10,
cis-12 CLA diminishes 5-HETE level in human breast cancer cells
[24].5. Conclusions
In summary, the results of our study showed that CLA daily supple-
mentation after carcinogen administration inﬂuenced LA and AA me-
tabolite levels in serum and tumours. However, the ratios of
eicosanoids having opposite effects, not concentrations of particular
compounds, appear to be better indicators of pathological processes.
Our experiment conﬁrms how various and difﬁcult is tumourigenesis
and the impact of diet on it remains questions requiring further
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